HomeSGX-LISTED COMPANIESLow Keng Huat (Singapore) Limited Half-Year Financial Results

Low Keng Huat (Singapore) Limited Half-Year Financial Results

Published on

spot_img

For the first half of FY2026, Low Keng Huat’s revenue and profit saw a significant downturn compared to the previous year. This was largely driven by the near completion of a major property development project. While the hotel and investment segments faced mixed results, the company managed to strengthen its financial position by reducing borrowings and improving its gearing ratio.

• A major residential project reached its final stages, leading to a sharp drop in revenue recognition for the property development segment

• Performance in the hotel segment was mixed, with one international property showing improvement while Singapore-based serviced apartments experienced declines

• The Group’s balance sheet strengthened, as cash from the completed project was used to significantly pay down debt

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...